Printer Friendly

Sarepta called top small-to-mid cap biotech pick for second half at BofA/Merrill.

BofA Merrill Lynch analyst Tazeen Ahmad called Sarepta (SRPT) his top small-to-mid cap biotech pick for the second half of the year, citing several near-term catalysts. Investors have mostly focused on m-dystrophin in Duchenne muscular dystrophy, or DMD, but he believes its pipeline in limb-girdle muscular dystrophy, or LGMD, is not yet fully reflected in the current valuation and thinks catalysts from LGMD will drive upside in the back half of 2019, Ahmad tells investors. Competitor Pfizer (PFE) reports clinical data at PPMD on June 28, which could be a catalyst for Sarepta, as could potential approval of Golodirsen in the U.S. by its August 19 PDUFA date and low dose functional benefit data from the LGMD2E study at WMS in October, said the analyst. He has a Buy rating and $200 price target on Sarepta shares.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jun 21, 2019
Words:138
Previous Article:U.S. equities are weaker.
Next Article:WWE's India / Middle East / China TV deals still to be done, says MKM Partners.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |